EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer

Suji Lee iD, Jee Yeon Kim iD, So Jeong Lee iD, Chung Su Hwang iD, Hyun Jung Lee iD, Kyung Bin Kim iD, Jung Hee Lee iD, Dong Hoon Shin iD, Kyung Un Choi iD, Chang Hun Lee iD, Gi Yeong Huh iD, Ahrong Kim iD

Medicina · 2024

DOI: 10.3390/medicina60050737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, 2024. Verfasst von Suji Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Pusan National University Hospital, Biomedical Research Institution, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: This study aimed to explore biomarker change after NAC (neoadjuvant chemotherapy) and to investigate biomarker expression as a prognostic factor in patients with residual disease (RD) after NAC. Materials and Methods: We retrospectively evaluated 104 patients with invasive breast cancer, who underwent NAC and surgery at Pusan National University Hospital from 2015 to July 2022. The expression of the biomarker was assessed, and the overall survival (OS) and disease-free survival (DFS) were investigated.

Results

After NAC, 24 patients (23.1%) out of 104 total patients had a pathological complete response (pCR). We found that changes in at least one biomarker were observed in 41 patients (51.2%), among 80 patients with RD. In patients with RD after NAC (n = 80), a subtype change was identified in 20 patients (25.0%). Any kind of change in the HER2 status was present 19 (23.7%) patients. The hormone receptor (HR)+/HER2+ subtype was significantly associated with better disease-free survival (DFS) (HR, 0.13; 95% CI, 0.02–0.99; p = 0.049). No change in p53 was associated with better DFS, and negative-to-positive change in p53 expression after NAC was correlated with worse DFS (p < 0.001). Negative-to-positive change in p53 was an independent, worse DFS factor in the multivariate analysis (HR,18.44; 95% CI, 1.86–182.97; p = 0.013).

Conclusions

Biomarker change and subtype change after NAC were not infrequent, which can affect the further treatment strategy after surgery. The expression change of p53 might have a prognostic role. Overall, we suggest that the re-evaluation of biomarkers after NAC can provide a prognostic role and is needed for the best decision to be made on further treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyBiomarkers, TumorHumansFemaleMiddle AgedRetrospective StudiesAdultAgedDisease-Free SurvivalChemotherapy, AdjuvantPrognosisErb-b2 Receptor Tyrosine KinasesSurvival Analysis

Stichwörter der Autor:innen

biomarkerbreast cancer subtypebreast cancersneoadjuvant chemotherapyp53prognostic factor

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, Pusan National University Hospital, Biomedical Research Institution, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea.
  • Department of Pathology, School of Medicine, Pusan National University, Beomeori, Mulgeum-eop, Yangsan 50612, Republic of Korea.
  • Department of Pathology, Yangsan Pusan National University Hospital, Medical Research Institute, Beomeori, Mulgeum-eop, Yangsan 50612, Republic of Korea.
  • Department of Pathology, Seegene Medial Foundation Busan, Joongangdaero 297, Busan 48792, Republic of Korea.

ORCID-Profile: Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim

Förderung

  • Pusan National University Research Grant

Zitieren

APA

Lee, S., Kim, J. Y., Lee, S. J., Hwang, C. S., Lee, H. J., Kim, K. B., Lee, J. H., Shin, D. H., Choi, K. U., Lee, C. H., Huh, G. Y., & Kim, A. (2024). Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer. Medicina. https://doi.org/10.3390/medicina60050737

Vancouver

Lee S, Kim JY, Lee SJ, Hwang CS, Lee HJ, Kim KB, et al. Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer. Medicina. 2024. doi:10.3390/medicina60050737

BibTeX
@article{Lee2024,
  author = {Lee, Suji and Kim, Jee Yeon and Lee, So Jeong and Hwang, Chung Su and Lee, Hyun Jung and Kim, Kyung Bin and Lee, Jung Hee and Shin, Dong Hoon and Choi, Kyung Un and Lee, Chang Hun and Huh, Gi Yeong and Kim, Ahrong},
  title = {Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer},
  journal = {Medicina},
  year = {2024},
  doi = {10.3390/medicina60050737}
}
Kostenlos starten →